SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
In a tough period for the biotechnology industry, UK-based NRG Therapeutics has raised £50 million ($67 million) in series B financing to take its lead compound into clinical trials. CEO Neil Miller ...
The MarketWatch News Department was not involved in the creation of this content. COPENHAGEN, Denmark, Oct. 9, 2024 /PRNewswire/ -- Antag Therapeutics, a leading biopharmaceutical company focused on ...
About one-third of all drugs approved by the Food and Drug Administration target the largest family of cell membrane receptors called G protein-coupled receptors (GPCRs). GPCRs are indispensable for ...
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results